The levels of cartonectin and procalcitonin in patients with chronic periodontitis and hypertension

• Published in: Türk biyokimya dergisi Vol. 48; no. 4; pp. 410 - 416
• Main Authors: Şahin Ata, Özlem, Canakci, Cenk Fatih, Özkan Karasu, Yerda
• Format: Journal Article
• Language: English
• Published: De Gruyter 12.06.2023
• Subjects: cartonectin; chronic periodontitis; essential hypertension; inflammation; procalcitonin
• ISSN: 1303-829X; 1303-829X
• DOI: 10.1515/tjb-2022-0237

Abstract Objectives This study aimed to examine the effects of chronic periodontitis and essential hypertension on serum and salivary cartonectin (CTRP3) and procalcitonin (ProCT) levels. Methods Sixty non-smokers were seperated into four groups as; 15 people with essential hypertension (EH) and chronic periodontitis (CP) (HT+ CP+), 15 with EH (HT+ CP−), 15 with CP (HT− CP+), 15 control (HT− CP−). PPD, CAL, PI and GI were measured. All groups had their serum and saliva samples collected. Serum and saliva procalcitonin (ProCT) were measured using an electroluminescence method, and cartonectin (CTRP3) levels were determined by enzyme-linked immunosorbent assay. Results When compared to the control group, serum and saliva cartonectin (CTRP3) levels were considerably lower in all groups (respectively p<0.0001, p<0.0001). The serum cartonectin (CTRP3) levels were substantially higher in the HT− CP+ group than in the HT+ CP− group (p=0.002). Serum procalcitonin (ProCT) concentrations were found to be lowest in the HT− CP− group and highest in the HT+ CP+ group. Serum ProCT concentrations did not vary significantly across groups (p=0.110). Salivary procalcitonin (ProCT) levels were below the detection limit in all groups. Conclusions When periodontitis coexist with hypertension in individuals, they may have adversely affect each other due to the same sathways in the pathogenesis of these two disorders. So we can suggest that, serum and saliva cartonectin (CTRP3) may play a role during hypertension and periodontal inflammation and represent a novel future therapeutic target.